Overview

* MeiraGTx ( MGTX ) Q3 revenue misses analyst expectations, declining significantly from last year

* Company enters strategic collaboration with Eli Lilly, including $75 mln upfront payment

* Net loss widens to $50.5 mln in Q3, driven by increased R&D expenses

Outlook

* Company anticipates Phase 2 data for AAV-hAQP1 in early 2027

* MeiraGTx ( MGTX ) plans Phase 3 study for AAV-GAD in Parkinson's disease soon

* Company expects riboswitch program to enter clinic for leptin deficiency

Result Drivers

* R&D - The increase of $6.3 million was primarily due to an increase in manufacturing costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $410,000 $6.96

Revenue mln (5

Analysts

)

Q3 EPS -$0.62

Q3 Net -$50.51

Income mln

Q3 -$46.05

Income mln

from

Operatio

ns

Q3 $46.46

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for MeiraGTx Holdings PLC ( MGTX ) is $29.00, about 70.1% above its November 12 closing price of $8.66

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)